(精选)Antibiotic Update教学课件.ppt

Antibiotic Update;Contents;Conventional antibiotics;Penicillins;Cephalosporins;Carbapenems;Quinolones;Aminoglycosides;Other antibiotics;Good news vs. bad news;Emerging and reemerging infectious diseasesAntibiotic resistanceNovel agents and their clinical uses;Gram-positive superbugs;Case 1;Community-acquired pneumonia (CAP);Community-acquired pneumonia (CAP);Community-acquired pneumonia (CAP);Case 1;Penicillin resistant Streptococcus pneumoniae(PRSP);Penicillin resistant Streptococcus pneumoniae(PRSP);Penicillin resistant Streptococcus pneumoniae(PRSP);Penicillin resistant Streptococcus pneumoniae(PRSP);Telithromycin (Ketek?);Linezolid (Zyvox?);Case 2;Skin and soft tissue infection;Staphylococcus aureus;Case 2;Methicillin resistant Staphylococcus aureus(MRSA);Methicillin resistant Staphylococcus aureus(MRSA);Methicillin resistant Staphylococcus aureus(MRSA);Methicillin resistant Staphylococcus aureus(MRSA);Methicillin resistant Staphylococcus aureus(MRSA);Methicillin resistant Staphylococcus aureus(MRSA);Case 2;VISA and VRSA;VISA and VRSA;VISA and VRSA;Linezolid (Zyvox?);Quinupristin/dalfopristin (Synercid?);Dalbavancin (Zeven?);Dalbavancin (Zeven?);Daptomycin (Cubicin?);Tigecycline (Tygacil?);Tigecycline (Tygacil?);Emerging and reemerging infectious diseasesAntibiotic resistanceNovel agents and their clinical uses;Gram-negative superbugs;Case 3;Acute cholangitis/cholecystitis;Acute cholangitis/cholecystitis;Case 3;Enterobacteriaceae;ESBL-producing Enterobacteriaceae;Case 3;Case 4;Pseudomonas aeruginosa;Pseudomonas aeruginosa;Case 4;Piperacillin vs. Tazocin;Piperacillin vs. Tazocin;Multidrug resistantGram-negative organisms;Colistin (Colomycin?);Case 5;Acinetobacter baumannii;Case 5;Acinetobacter baumannii;Case 6;Mycobacterium tuberculosis;Mycobacterium tuberculosis;Case 6;Multidrug Resistant TB;Multidrug Resistant TB;Multidrug Resistant TB;Multidrug Resistant TB;Tuberculosis;Case 6;Extensive Drug Resistant TB ;Extensive Drug Resistant TB;Extensive Dr